CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma

被引:2
|
作者
Shen, Mingfang [1 ]
Zhang, Yunfeng [1 ]
Tang, Lun [1 ]
Fu, Qinyan [1 ]
Zhang, Jiawei [2 ]
Xu, Yang [2 ]
Zeng, Hui [1 ]
Li, Yuan [1 ]
机构
[1] First Hosp Jiaxing, Dept Hematol, Jiaxing 314001, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hematol, Hangzhou 310009, Zhejiang, Peoples R China
关键词
CDC6; Diffuse large B cell lymphoma; Cell cycle; Apoptosis; Prognosis; DNA-REPLICATION; CANCER; EXPRESSION; ACTIVATION; CHECKPOINT; INITIATION; PROTEINS;
D O I
10.1186/s12885-023-11186-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Cell division cycle 6 (CDC6) is a key licensing factor in the assembly of pre-replicative complexes at origins of replication. The role of CDC6 in the pathogenesis of in diffuse larger B-cell lymphoma (DLBCL) remains unknown. We aim to investigate the effects of CDC6 on the proliferation, apoptosis and cell cycle regulation in DLBCL cells, delineate its underlying mechanism, and to correlate CDC6 expression with clinical characteristics and prognosis of patients with DLBCL.Methods Initial bioinformatic analysis was performed to screen the potential role of CDC6 in DLBCL. Lentiviral constructs harboring CDC6 or shCDC6 was transfected to overexpress or knockdown CDC6 in SUDHL4 and OCI-LY7 cells. The cell proliferation was evaluated by CCK-8 assay, cell apoptosis was detected by Annexin-V APC/7-AAD double staining, and cell cycle was measured by flow cytometry. Real time quantitative PCR and western blot was used to characterize CDC6 expression and its downstream signaling pathways. The clinical data of DLBCL patients were retrospectively reviewed, the CDC6 expression in DLBCL or lymph node reactive hyperplasia tissues was evaluated by immunohistochemistry.Results In silico data suggest that CDC6 overexpression is associated with inferior prognosis of DLBCL. We found that CDC6 overexpression increased SUDHL4 or OCI-LY7 cell proliferation, while knockdown of CDC6 inhibited cell proliferation in a time-dependent manner. Upon overexpression, CDC6 reduced cells in G1 phase and did not affect cell apoptosis; CDC6 knockdown led to significant cell cycle arrest in G1 phase and increase in cell apoptosis. Western blot showed that CDC6 inhibited the expression of INK4, E-Cadherin and ATR, accompanied by increased Bcl-2 and deceased Bax expression. The CDC6 protein was overexpressed DLBCL compared with lymph node reactive hyperplasia, and CDC6 overexpression was associated with non-GCB subtype, and conferred poor PFS and OS in patients with DLBCL.Conclusion CDC6 promotes cell proliferation and survival of DLBCL cells through regulation of G1/S cell cycle checkpoint and apoptosis. CDC6 is overexpressed and serves as a novel prognostic marker in DLBCL.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma
    Mingfang Shen
    Yunfeng Zhang
    Lun Tang
    Qinyan Fu
    Jiawei Zhang
    Yang Xu
    Hui Zeng
    Yuan Li
    BMC Cancer, 23
  • [2] Hypomethylation and the Resultant Overexpressed PARM1: a Biomarker for Poor Prognosis of Diffuse Large B-cell Lymphoma
    Cao, Baoping
    Guo, Xiaochuan
    Wang, Bin
    Wang, Weixia
    Han, Dong
    Zhang, Weijing
    Zhong, Kaili
    DISCOVERY MEDICINE, 2022, 33 (168) : 27 - 40
  • [3] Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection
    Tsai, Yu-Fen
    Liu, Yi-Chang
    Yang, Ching-, I
    Chuang, Tzer-Ming
    Ke, Ya-Lun
    Yeh, Tsung-Jang
    Gau, Yuh-Ching
    Du, Jeng-Shiun
    Wang, Hui-Ching
    Cho, Shih-Feng
    Hsu, Chin-Mu
    Wu, Pey-Fang
    Huang, Ching-, I
    Huang, Chung-Feng
    Yu, Ming-Lung
    Dai, Chia-Yen
    Hsiao, Hui-Hua
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
  • [4] Strong HDAC6 Expression Is Associated with Poor Prognosis of Diffuse Large B-Cell Lymphoma
    Zhou, X.
    Cai, Y.
    Cui, W.
    Wang, W.
    Liu, Z.
    Wei, P.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 863 - 864
  • [5] Nur 77 Is a Poor Prognostic Factor in Diffuse Large B-Cell Lymphoma
    Almiski, Muhamad Sadek
    Kurrer, Michael
    Levi, Edi
    FASEB JOURNAL, 2008, 22
  • [6] Nur 77 is a poor prognostic factor in diffuse large B-cell lymphoma
    Almiski, S.
    Razumilava, N.
    Kurrer, M.
    Frank, J.
    Levi, E.
    LABORATORY INVESTIGATION, 2008, 88 : 245A - 245A
  • [7] Nur 77 is a poor prognostic factor in diffuse large B-cell lymphoma
    Almiski, S.
    Razumilava, N.
    Kurrer, A.
    Frank, J.
    Levi, E.
    MODERN PATHOLOGY, 2008, 21 : 245A - 245A
  • [8] Chromosomal Instability Substantiates Poor Prognosis in Patients with Diffuse Large B-cell Lymphoma
    Bakhoum, Samuel F.
    Danilova, Olga V.
    Kaur, Prabhjot
    Levy, Norman B.
    Compton, Duane A.
    CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7704 - 7711
  • [9] Clinicopathologic significance of DNA replication licensing factors in head and neck diffuse large B-cell lymphoma
    Etemad-Moghadam, Shahroo
    Ghaseminejad-Bandpey, Ali
    Mahmoodzadeh, Habibollah
    Alaeddini, Mojgan
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2022, 133 (04): : 462 - 469
  • [10] B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma
    Ci, Weimin
    Polo, Jose M.
    Melnick, Ari
    CURRENT OPINION IN HEMATOLOGY, 2008, 15 (04) : 381 - 390